

Perspective on the Innovative Medicines Initiative 2 (IMI2)



Dr Ruxandra Draghia-Akli, MD PhD Director Health

DG Research and Innovation European Commission

> * IMI2 Open Into Day Brussels, 30 September 2014





IMI2 is an integral part of our strategy for EU health research











At the forefront



2003 EDCTP - 1st "Article 169

Initiative"

2008 IMI - 1st "Article 171

Initiative" at DG Research

2009

1st Joint Programming initiative on Alzheimer's

2010 Innovation Partnerships on

Active & Healthy Ageing

2010/11 Large-scale international research initiatives on

Epigenome/Blueprint, rare

diseases...

2012 "SMEs for Innovation" call &

1st Innovation Inducement

Prize



IMI2 scope and objectives

- IMI2 will expand the scope of IMI1 to cover the entire medical research and innovation value chain:
 - Actively involve life science industries other than pharmaceuticals; for example the vaccine, the animal health or the biomedical imaging industry
- Enable top quality research and innovations with great public health benefits and commercial possibilities
- Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future:
 - Develop new therapies for diseases with high unmet need, such as Alzheimer's disease, and limited market incentives, such as antimicrobial resistance





IMI 2 strategic research agenda

Priority Medicines for Europe and the World 2013 Update


Warren Kaplan, Veronika J. Wirtz, Aukje Mantel-Teeuwisse, Pieter Stolk, Béatrice Duthey, Richard Laing

9 July 2013











IMI2 budget and funding

- Budget from public and private partners: 3.27 Billion Euro; 1.638 Billion Euro EU contribution:
 - Up to EUR 1 425 million to match EFPIA's contribution
 - ▶ Up to EUR 213 million to match additional contributions from other future Members or Associated Partners
- All EU funding goes to SMEs, medium-sized industrial partners (annual sales less than €500 million), academia, patient organisations and regulatory agencies
- Simplified funding rates & reporting (aligned with H2020)



How will IPR be handled?

Similarly to the first phase, IMI2 will aim to:

- Promote knowledge creation together with its disclosure and exploitation
- Achieve a fair allocation of rights
- Reward innovation
- Achieve a broad participation of private and public entities

IP rules only depart from H2020 rules when required by the specific operating needs of IMI2






IMI2 aligned with Horizon 2020

- Rules for participation apply, except for derogations on IPR and eligibility for funding
- Simplifications in Horizon 2020 also apply to IMI2 (funding rates, indirect cost!)
- Publication of calls on Participant Portal (and on IMI website)
- Search function includes IMI2 topics





Horizon 2020 dedicated SME Instrument - Phase 1 2014 H2020-SMEINST-1-2014 Deadlines: 18/06/2014 24/09/2014

17/12/2014 Opening Date: 03/03/2014



